Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | FABP1 | P07148 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064235 | 0.84 | PKM (0.61) | ALDH1A1GAAPKMMEN1KMT2A | |
| SCHEMBL9950645 | 0.84 | MAPK1 (0.55) | ALDH1A1GAAFABP1MAPTL3MBTL1 | |
| SCHEMBL18711905 | 0.79 | L3MBTL1 (0.64) | ALDH1A1GAAFABP1MAPTMEN1 | |
| SCHEMBL4035342 | 0.78 | MAPK1 (0.59) | ALDH1A1GAAMAPTKMT2ALMNA | |
| SCHEMBL4032606 | 0.78 | GAA (0.57) | ALDH1A1GAAMAPTKMT2ALMNA | |
| SCHEMBL9950690 | 0.78 | PKM (0.83) | ALDH1A1GAAPKMMEN1KMT2A | |
| SCHEMBL18701946 | 0.78 | L3MBTL1 (0.62) | ALDH1A1GAAFABP1MAPTMEN1 | |
| SCHEMBL9951626 | 0.77 | PKM (0.73) | ALDH1A1GAAPKMMEN1KMT2A | |
| SCHEMBL2961832 | 0.76 | ALDH1A1 (1.00) | ALDH1A1GAAFABP1MAPTMEN1 | |
| SCHEMBL6230533 | 0.75 | MAPK1 (0.53) | ALDH1A1GAAPKMMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448581-B1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | ALDH1A1 1240/4885GAA 1430/4885FABP1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.